WHO ICTRP trial
A study to assess safety, tolerability, and anticancer activity of ISB 1442
CTRI/2024/04/065308 · Clinical Trials Registry India (CTRI) · Recruiting
Key facts
| Trial ID | CTRI/2024/04/065308 |
|---|---|
| Public title | A study to assess safety, tolerability, and anticancer activity of ISB 1442 |
| Scientific title | A Phase 1/2, First-in-Human, Multicentre, Open-Label, Dose Escalation and Dose-Expansion Study of Single-Agent ISB 1442 in Patients with Relapsed/Refractory Multiple Myeloma - NIL |
| Primary sponsor | Ichnos Sciences SA |
| Secondary sponsors | Glenmark Pharmaceuticals Ltd Glenmark House B D Sawant Marg |
| Registry | Clinical Trials Registry India (CTRI) |
| Recruitment status | Recruiting |
| Study type | Interventional |
| Phase | Phase 1/ Phase 2 |
| Countries | United States of America;Australia;India |
| Conditions | Health Condition 1: C900- Multiple myeloma |
| Interventions | Intervention1: ISB 1442: Dosage Form: Lyophilized powder for solution for injection Dose: Starting dose from 6 mg. Dosage Frequency: Weekly, dosing on Days 1, 8, 15, and 22 of each 28-day treatment cycles Mode of Administration… |
| Registration date | May 4, 2024 |
| Target size | 121 |
| Secondary IDs | Protocol No: ISB 1442-101; Version No 3.1; Dated 19-Oct-2023 |
| Registry page | ctri.nic.in |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: